OnKure Therapeutics
OKUR
47 hedge funds and large institutions have $50.1M invested in OnKure Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 8 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
0.1% more ownership
Funds ownership: 93.59% → 93.69% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 51 → 47 (-4)
49% less capital invested
Capital invested by funds: $99.2M → $50.1M (-$49.1M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$1.41M |
| 2 |
SC
Shay Capital
New York
|
+$765K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$691K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$593K |
| 5 |
CF
Cantor Fitzgerald
New York
|
+$534K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$1.88M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.4M |
| 3 |
Millennium Management
New York
|
-$1.24M |
| 4 |
6CM
683 Capital Management
New York
|
-$373K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$177K |
OKUR Hedge Fund Activity: Q1 2025 in Review
47 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2025, worth a combined $50.1M — down 49% from $99.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OKUR and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Affinity Asset Advisors, adding an estimated $1.41M. The largest seller was Altium Capital Management, exiting entirely with an estimated $1.88M sold.
- 47 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2025, down from 51 in Q4 2024.
- Funds reported $50.1M of OnKure Therapeutics stock for Q1 2025, down 49% quarter-over-quarter.
- 4 funds opened new OnKure Therapeutics positions in Q1 2025 and 8 closed out, a net change of -4 holders.
- The largest OnKure Therapeutics buyer in Q1 2025 was Affinity Asset Advisors, an estimated $1.41M added.
- The largest OnKure Therapeutics seller in Q1 2025 was Altium Capital Management, an estimated $1.88M sold.
Based on aggregated 13F filings for Q1 2025.